← Back to Screener
Protagonist Therapeutics, Inc (PTGX)
Price$97.38
Value ScoreF
Growth ScoreD
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)0.27%
Price vs S&P 500 (4W)-1.98%
VGM Score43.70
Market Capitalization$6.26B
P/E Ratio (Annual)21.85x
All Metrics
P/CF (Annual)108.59x
Book Value / Share (Quarterly)$10.21
P/TBV (Annual)4.61x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)20.07%
Cash Flow / Share (Quarterly)$-1.84
Price vs S&P 500 (YTD)3.34%
Net Profit Margin (TTM)-154.88%
EPS (TTM)$-1.80
10-Day Avg Trading Volume0.60M
EPS Excl Extra (TTM)$-1.80
Revenue Growth (5Y)9.96%
EPS (Annual)$-2.05
ROI (Annual)-21.17%
Net Profit Margin (5Y Avg)-257.85%
Cash / Share (Quarterly)$8.53
P/E Basic Excl Extra (TTM)130.98x
Revenue Growth QoQ (YoY)99.03%
P/E Normalized (Annual)21.85x
ROA (Last FY)-19.48%
Revenue Growth TTM (YoY)-64.36%
EBITD / Share (TTM)$-2.15
ROE (5Y Avg)-20.96%
Operating Margin (TTM)-192.36%
Cash Flow / Share (Annual)$0.90
P/B Ratio9.55x
P/B Ratio (Quarterly)10.26x
Net Income / Employee (Annual)$-986,000
EV / Revenue (TTM)81.94x
Net Interest Coverage (TTM)-7.30x
ROA (TTM)-16.47%
EV / EBITDA (TTM)296.80x
EPS Incl Extra (Annual)$-2.05
Current Ratio (Annual)12.71x
Quick Ratio (Quarterly)17.64x
3-Month Avg Trading Volume0.71M
52-Week Price Return80.94%
EV / Free Cash Flow (Annual)108.22x
P/E Incl Extra (TTM)130.98x
Revenue / Employee (TTM)$561,100
Tangible BV / Share (Quarterly)$5.24
P/S Ratio (Annual)136.10x
Asset Turnover (Annual)0.07x
52-Week High$107.84
Operating Margin (5Y Avg)-279.15%
EPS Excl Extra (Annual)$-2.05
CapEx CAGR (5Y)27.60%
Tangible BV CAGR (5Y)12.32%
26-Week Price Return8.20%
Quick Ratio (Annual)12.58x
13-Week Price Return6.53%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)17.76x
Enterprise Value$6.07B
Revenue / Share Growth (5Y)-2.75%
Asset Turnover (TTM)0.11x
Book Value / Share Growth (5Y)8.95%
Revenue / Employee (Annual)$348,600
Pretax Margin (Annual)-281.01%
Cash / Share (Annual)$9.07
3-Month Return Std Dev46.74%
Net Income / Employee (TTM)$-869,000
ROE (Last FY)-21.17%
Net Interest Coverage (Annual)-376.80x
EPS Basic Excl Extra (Annual)$-2.05
P/FCF (TTM)15.92x
Receivables Turnover (TTM)4.85x
EV / Free Cash Flow (TTM)116.03x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.80
Receivables Turnover (Annual)9.87x
ROI (TTM)-17.76%
P/S Ratio (TTM)84.56x
Pretax Margin (5Y Avg)-257.29%
Revenue / Share (Annual)$0.72
Tangible BV / Share (Annual)$4.37
Forward P/E44.87x
Price vs S&P 500 (52W)56.57%
P/E Ratio (TTM)130.98x
EPS Growth TTM (YoY)-76.41%
Year-to-Date Return11.50%
5-Day Price Return2.59%
EPS Normalized (Annual)$-2.05
ROA (5Y Avg)-18.42%
Net Profit Margin (Annual)-282.83%
Month-to-Date Return-2.19%
Cash Flow / Share (TTM)$-2.59
EBITD / Share (Annual)$-2.47
Operating Margin (Annual)-343.63%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)115.06x
ROI (5Y Avg)-20.96%
P/E Excl Extra (TTM)130.98x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.80
P/TBV (Quarterly)3.29x
P/B Ratio (Annual)8.88x
Pretax Margin (TTM)-155.78%
Book Value / Share (Annual)$9.82
Price vs S&P 500 (13W)-1.72%
Beta1.81x
P/FCF (Annual)111.67x
Revenue / Share (TTM)$1.05
ROE (TTM)-17.76%
52-Week Low$49.38
vGradeF
gGradeD
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 260.05est. -0.54
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.21
4.21
4.21
4.25
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PTGXProtagonist Therapeutics, Inc | F | D | B | $97.38 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Protagonist Therapeutics is a biopharmaceutical company developing peptide-based therapeutics across inflammation, hematology, and metabolic diseases using a proprietary platform. Its clinical pipeline includes rusfertide for polycythemia vera and icotrokinra for inflammatory conditions, complemented by preclinical programs in obesity and iron metabolism. The company advances its candidates through internal research and strategic collaborations.